STING
7 articles
PharmacologyBritish Journal of Pharmacology
Radiation speeds up plaque growth through a macrophage mtDNA–cGAS–STING–NLRP3 loop
- Ionising radiation worsened atherosclerosis in ApoE-knockout mice, with more pyroptosis-related gene expression in plaque macrophages.
- Radiation drove mitochondrial DNA into the cytoplasm, activating cGAS/STING/TBK1; phosphorylated IRF3 then bound the NLRP3 promoter and raised its transcription.
- Caspase-1 deletion or macrophage-specific cGAS knockdown blunted the radiation effect.
The genetic arms are convincing for the mechanism, but nobody has yet shown a pharmacological intervention: a STING or NLRP3 inhibitor given after irradiation would tell us whether this is druggable or just explanatory. STING inhibitors also carry a theoretical risk for the very antitumour immunity radiotherapy relies on, so any translation has to protect the heart without blunting the tumour response.
PharmacologyBiochemical Pharmacology
Endothelial cGAS–STING activation drives aortic aneurysm; blocking it helps in mice
- Single-cell data from mouse and human aneurysms placed cGAS–STING activation mainly in endothelial cells, with higher expression in ruptured than in stable human aneurysms.
- In angiotensin II–induced mouse aneurysm, the cGAS inhibitor RU.521 or the STING antagonist STING-IN-2 reduced aneurysm incidence, aortic dilation and structural damage.
- Human aneurysm tissue showed raised cGAS, STING and TBK1, and bioinformatics suggested DHFR deficiency may link DNA damage to pathway activation.
Two different nodes, cGAS and STING, giving the same phenotype is reassuring, but both are tool compounds and angiotensin II models usually start dosing early. Translatability hinges on treating after an aneurysm is established, with rupture as the endpoint. I'd also ask whether chronic systemic STING inhibition, with its effect on interferon-based antiviral defence, is tolerable in an older vascular population.
PharmacologyBiochemical Pharmacology
Blocking cGAS-STING in vessel walls curbs aortic aneurysm in mice
- Single-cell data from mouse and human aneurysm tissue place cGAS-STING signaling mainly in endothelial cells, with higher expression in ruptured than stable human lesions.
- In angiotensin II-driven mouse aneurysm, the pathway was switched on; either a cGAS inhibitor or a STING antagonist lowered aneurysm occurrence and tissue damage and improved endothelial mitochondria.
- Patient aneurysm samples also showed elevated pathway proteins, and DHFR loss emerged as a possible link between DNA damage and activation.
Two inhibitors, one mouse model: that's thin. Angiotensin II aneurysm is acute and hypertension-driven, a poor mimic of slow human AAA, and RU.521 is far more potent on mouse than human cGAS. Human evidence is correlative expression, not genetics. Next study needs dosing after aneurysm is established, exposure data, and a second model such as elastase.
Medicinal ChemistryJournal of Medicinal Chemistry
An oral STING inhibitor that blocks palmitoylation shows efficacy in inflammation models
- Researchers built a tetrahydropyrazolo[1,5-a]pyrazine series as inhibitors of STING, the innate-immune adaptor behind several interferonopathies and autoimmune conditions.
- The lead, compound 37, combined strong cellular STING inhibition with good oral exposure and a clean safety read.
- Mechanistically it prevents STING palmitoylation, which in turn shuts down downstream signaling.
- Oral dosing reduced inflammation in acute chemical-challenge and Trex1-deficient mouse models, among others.
STING inhibitors have mostly been tool compounds or covalent binders, so a non-covalent-looking, orally dosed chemotype that acts by blocking palmitoylation is a different handle on the target. I would want to know whether it truly binds the Cys91 pocket or acts upstream, because that decides selectivity versus other palmitoylated proteins. The Trex1 mouse data is the convincing part for an autoimmune indication.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Oral STING inhibitor D4 protects against severe acute pancreatitis in mice
- SAR work identified D4, which binds STING directly and blocks its oligomerization and downstream TBK1/IRF3 signalling.
- In macrophages it restored phagocytosis, autophagic flux and mitochondrial function while dampening NLRP3-linked pyroptosis.
- D4 was orally exposed and well tolerated at high dose, and cut pancreatic injury and enzyme levels in a caerulein/LPS model; STING knockdown looked similar.
Most STING programs chase agonists for oncology; an orally available inhibitor for an acute inflammatory indication is a different bet. The knockdown phenocopy is reassuring on mechanism, but I'd want to know how it behaves across species, since STING ligand pockets are notoriously species-dependent, and whether an acute dosing window is realistic in patients.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Boronic acid ENPP1 inhibitors stay active across tumor-relevant pH
- ENPP1 hydrolyzes cGAMP in the tumor microenvironment and so dampens STING-driven antitumor immunity.
- Inspired by the phosphate-based inhibitor STF-1084, the team made non-nucleotide inhibitors with a boronic acid zinc-binding group, leading to compound 36, which stays potent across pH.
- Compound 36 boosted cGAMP-mediated STING activation in vitro and gave tumor growth inhibition as monotherapy in a syngeneic CT26 model, with a synergistic effect alongside oxaliplatin and no observed toxicity.
Phosphate- and phosphonate-type ENPP1 binders have always struggled with permeability and exposure, so swapping in a boronic acid zinc binder is a cleaner route. Designing for acidic-pH activity is the smart part, since that is where the enzyme works. Single-agent efficacy by IP dosing is modest, so oral exposure and boronic acid stability are my next questions.
Medicinal ChemistryNature Communications (Nature)
Approved Ataxia Drug Repurposed to Degrade STING via 'Molecular Crowbar'
- Omaveloxolone is an FDA-approved Nrf2-activating drug, originally approved for Friedreich's ataxia, now repurposed as a STING-targeting agent.
- It binds the base of STING's ligand-binding domain, destabilizing the protein's folded structure.
- This triggers K27-linked polyubiquitination of STING and its subsequent degradation by the proteasome — a "molecular crowbar" mechanism.
- Unlike classical PROTAC-style bifunctional degraders, omaveloxolone acts as a single small molecule, directly destabilizing STING rather than using a ligand-linker-E3-ligase construct.
- In aged mice, omaveloxolone treatment reduced STING-pathway-driven inflammation, a hallmark of age-related "inflammaging."
A monovalent degrader that's neither a classic PROTAC nor a molecular glue — that's the interesting bit. "Molecular crowbar" reads like marketing, but mechanistically it sounds like ligand-induced conformational destabilization exposing a degron: closer to hydrophobic-tag logic than E3-recruitment chemistry, no linker or ternary-complex engineering required. Chemically elegant, if it holds up. The real draw is that omaveloxolone's safety and PK are already banked — repurposing means skipping a decade of tox work if this translates. But my triage instinct says this is serendipitous polypharmacology, not designed SAR; the Nrf2 pharmacophore was never built for STING's pocket. It's also secondary-sourced with no primary structural data yet — I'd want a co-crystal or HDX-MS confirming direct engagement before trusting the crowbar story over generic proteostasis stress.